Ligand Pharmaceuticals: Das hochprofitable Lizenz-Kraftwerk der Biotech-Branche
Dank eines rein auf Lizenzen und Lizenzgebühren basierenden Geschäftsmodells filtert Ligand Pharmaceuticals die extremen Entwicklungsrisiken der Branche aus und…
277,000€
-1,07%
Echtzeit-Aktienkurs Ligand Pharmaceuticals
Bid:
Ask:
Nachrichten zur Ligand Pharmaceuticals Aktie
LGND: XOMA Buy Adds 100+ Assets
By John Vandermosten, CFANASDAQ: LGND | NASDAQ: XOMAIn an April 27th press release, Ligand Pharmaceuticals, Inc. (NASDAQ: LGND) announced that it…
Ligand Pharmaceuticals überzeugt mit hochmargigem Lizenzgeschäft
Ligand Pharmaceuticals (LGND) habe ich unter den Wachstumsaktien gerade ganz oben auf meiner Breakout-Watchlist. Das Unternehmen verfolgt als hochprofitabler Biopharma-Royalty-Aggregator…
Ligand Pharmaceuticals: Dominanz im Biopharma-Royalty-Markt – Lizenzeinnahmen steigen bis 2030 um jährlich 23 %!
Ligand Pharmaceuticals überzeugt innerhalb der Biopharma-Industrie durch ein hochmargiges, risikoarmes Lizenzmodell in einem über 29 Mrd. USD großen Royalty-Markt.…
Ligand Pharmaceuticals offers high-margin exposure to biopharma growth, BofA says
Bank of America has initiated coverage of Ligand Pharmaceuticals Inc (NASDAQ:LGND) with a Buy rating and a $244 price target,…
Kaufalarm bei Ligand Pharmaceuticals: Nach +60 % Umsatzwachstum wird jetzt strategisch in den Pharma-Markt investiert!
Ligand Pharmaceuticals (LGND) konzentriert sich darauf, Partnerunternehmen bei der Erforschung und Entwicklung lebensrettender Therapeutika finanziell und technologisch zu unterstützen. In…
LGND: New Year Program Updates
By John Vandermosten, CFANASDAQ:LGNDREAD THE FULL LGND RESEARCH REPORTIn the wake of the December analyst day, Ligand Pharmaceuticals, Inc.’s (NASDAQ:LGND)…
A biotech stock for investors scared to invest in the risky industry
Citi sees shares of Ligand Pharmaceuticals soaring another 46% on top of an already impressive year-to-date rally.…
Ligand (LGND) Q3 2025 Earnings Call Transcript
Image source: The Motley Fool.DATEThursday, Nov. 6, 2025, at 8:30 a.m. ETCALL PARTICIPANTSChief Executive Officer — Todd DavisChief Financial Officer…
Ligand Pharmaceuticals stock hits 52-week high at 186.46 USD By Investing.com
Ligand Pharmaceuticals stock hits 52-week high at 186.46 USD…
Ligand Pharmaceuticals unterstreicht Resilienz im Biotech-Sektor
Ligand Pharmaceuticals ist ein US-Biopharmaunternehmen mit Sitz in Jupiter (Florida), das sich auf ein Lizenz- und Royalty-Modell spezialisiert hat: Anstatt…
Ligand Pharmaceuticals: Attractive Royalty Model Powers Forward
…
Ligand Pharmaceuticals: Buy This Strong Growing Pharma And Get A Stake In Dozens Of Therapies
…
Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer
Mr. Korenberg is a seasoned executive with significant operational and financial leadership experience, including senior roles at Ligand Pharmaceuticals (NASDAQ:…
invIOs raises €8.2 million in a Series A to finance pipeline progress in immuno-oncology
VIENNA, Oct. 15, 2024 (GLOBE NEWSWIRE) -- invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies…
Ligand Pharmaceuticals Incorporated 2024 Q2 - Results - Earnings Call Presentation
…
Ligand Pharmaceuticals reports mixed Q2 results; reaffirms FY24 outlook
…
Ligand Pharmaceuticals: Solid Performer Performing Solidly
…
Ligand (LGND) Beats Q1 Earnings, Misses Sales Estimates
Ligand Pharmaceuticals (LGND) reports mixed first-quarter results. Management reiterates the 2024 financial outlook.…
Ligand Pharmaceuticals Incorporated 2024 Q1 - Results - Earnings Call Presentation
…
Ligand (LGND) Q4 Earnings Surpass Estimates, Stock Surges
Ligand Pharmaceuticals (LGND) reports encouraging fourth-quarter results as earnings and sales beat estimates. Management reiterates the 2024 financial outlook.…